Answers are grounded in this paper and cite their sources.
Human parvovirus B19 is the causative agent of various clinical diseases like erythema infectiosum, transient aplastic crisis, fetal hydrops, reactive arthritis, and rarely potentially fatal organ diseases. The worldwide seroprevalence of parvovirus B19 has been assessed to be about 40-60%. It has been shown that parvoviruses can also infect new host species, adapt, and co-evolve. A comprehensive genomic surveillance is essential to gain a better insight in the adaptation, evolution, and also epidemics of parvoviruses. In the scope of the large parvovirus B19 epidemic 2023/24 following the SARS-CoV-2 pandemic, we developed a rapid and convenient system to analyze parvovirus B19 genomes directly from patient samples by next-generation sequencing. We utilized this system to study the part of the unusual outbreak in Southern Germany (Central Franconia), comprising the counties Nuremberg, Fuerth, and Erlangen. This detected a certain genetic diversity within the analyzed samples and identified shared mutations in comparison to reference sequences. Here, two phylogenetically distinct groups were observed, compatible with the co-circulation of at least two B19V lineages in the region and a putative new genotype of human parvovirus B19, possibly induced by immunosuppression was identified. We established a new, quick, and convenient surveillance system for human parvovirus B19 that enables the analysis of outbreaks and monitoring of viral genetic changes.
No takes yet. Share an insight, caveat, or question.
Cordsmeier et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: